Heidelberg Pharma AG (HPHA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Heidelberg Pharma AG (HPHA) has a cash flow conversion efficiency ratio of -0.299x as of May 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-5.53 Million ≈ $-6.46 Million USD) by net assets (€18.52 Million ≈ $21.65 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Heidelberg Pharma AG - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Heidelberg Pharma AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Heidelberg Pharma AG (HPHA) financial obligations for a breakdown of total debt and financial obligations.
Heidelberg Pharma AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Heidelberg Pharma AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Multitude SE
LSE:0R4W
|
0.115x |
|
CSC Steel Holdings Bhd
KLSE:5094
|
0.004x |
|
D-Box Technologies Inc.
TO:DBO
|
0.058x |
|
Betr Entertainment Ltd
AU:BBT
|
-0.135x |
|
BANK OF JIUJIANG H YC1
F:BJ8
|
N/A |
|
YFC-BonEagle Electric Co Ltd
TWO:6220
|
0.174x |
|
Abonmax Co Ltd
TW:2429
|
-0.075x |
|
TH Plantations Bhd
KLSE:5112
|
0.049x |
Annual Cash Flow Conversion Efficiency for Heidelberg Pharma AG (2016–2024)
The table below shows the annual cash flow conversion efficiency of Heidelberg Pharma AG from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see HPHA market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-11-30 | €30.87 Million ≈ $36.09 Million |
€-29.59 Million ≈ $-34.59 Million |
-0.959x | -40.46% |
| 2023-11-30 | €49.34 Million ≈ $57.68 Million |
€-33.67 Million ≈ $-39.37 Million |
-0.682x | -413.10% |
| 2022-11-30 | €66.64 Million ≈ $77.91 Million |
€-8.86 Million ≈ $-10.36 Million |
-0.133x | +96.65% |
| 2021-11-30 | €6.70 Million ≈ $7.83 Million |
€-26.61 Million ≈ $-31.11 Million |
-3.973x | -185.96% |
| 2020-11-30 | €12.88 Million ≈ $15.06 Million |
€-17.89 Million ≈ $-20.92 Million |
-1.389x | -164.54% |
| 2019-11-30 | €16.29 Million ≈ $19.05 Million |
€-8.56 Million ≈ $-10.00 Million |
-0.525x | -36.17% |
| 2018-11-30 | €25.89 Million ≈ $30.26 Million |
€-9.98 Million ≈ $-11.67 Million |
-0.386x | -79.83% |
| 2017-11-30 | €37.02 Million ≈ $43.28 Million |
€-7.94 Million ≈ $-9.28 Million |
-0.214x | +67.98% |
| 2016-11-30 | €9.76 Million ≈ $11.41 Million |
€-6.53 Million ≈ $-7.64 Million |
-0.670x | -- |
About Heidelberg Pharma AG
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, the United States, and internationally. Its lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company develops HDP-102, an antibody and the compound Amaniti… Read more